Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting

CAMBRIDGE, Mass., April 06, 2023 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting... | April 6, 2023

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,San Diego ,California ,United States ,Hilton Bayfront ,Karin Hellsvik ,Matthew Netherton ,Asadm Taherbhoy ,Michael Lampe ,Hans Vitzthum ,Foghorn Therapeutics Inc ,Therapeutics Inc ,Linkedin ,Nasdaq ,Exchange Commission ,Twitter ,Company Annual Report On Form ,Company Phase ,Annual Drug Discovery Chemistry ,Targeting Transcription Factor ,Drug Discovery ,Selective Heterobifunctional Degrader ,Senior Director ,Medicinal Chemistry ,Gene Traffic ,Annual Report ,Foghorn Therapeutics ,Lifesci Advisors ,Foghorn Therapeutics Inc Stock Exchange ,News ,Information ,Press Release ,Pril ,023 ,Herapeutics ,Biotechnology ,Company ,Ioneering ,Few ,Glass ,F ,Medicines ,Hat ,Treat ,Serious ,Diseases ,Y Fhtx Us3441741077 ,